Attovia Therapeutics
Hubert Chen currently serves as the Chief Medical Officer at Attovia Therapeutics since March 2024. Previously, Hubert Chen was the Senior Vice President of Clinical Development at Krystal Biotech, Inc. from October 2021 to March 2024. Hubert Chen's extensive experience at Genentech from 2011 to September 2021 includes roles such as Principal Medical Director, Senior Medical Director, Medical Director, and Associate Medical Director. Prior to Genentech, Hubert Chen held academic and clinical positions at UCSF Medical Center from 2002 to 2011, where responsibilities included Assistant Professor of Medicine and Clinical Instructor. Hubert Chen completed an Internal Medicine Residency at Stanford University Medical Center from 1998 to 2001. Educational qualifications include an MD from Stanford University School of Medicine, an MPH in Quantitative Methods from Harvard T.H. Chan School of Public Health, and a BA in Molecular Biology from Pomona College.
This person is not in any offices
Attovia Therapeutics
Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches. By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.